Details
Stereochemistry | ACHIRAL |
Molecular Formula | C24H23FN4O3 |
Molecular Weight | 434.4628 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N4CCN(CC4)C(=O)C5CC5
InChI
InChIKey=FDLYAMZZIXQODN-UHFFFAOYSA-N
InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)
Molecular Formula | C24H23FN4O3 |
Molecular Weight | 434.4628 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880823/
Curator's Comment: Description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880823/
Olaparib is an oral inhibitor of poly (ADP-ribose) polymerase enzymes, including PARP1, PARP2, and PARP3 which are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has shown activity in ovarian and breast tumors with known BRCA mutations and was the first FDA approved drug in this class. Lynparza (olaparib) is indicated for treatment of gBRCA-mutated advanced ovarian cancer. Its use together with other chemotherapy medicines can lead to increased effects on the blood resulting in reduction in the numbers of white blood cells and platelets, and anaemia.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P09874 Gene ID: 142.0 Gene Symbol: PARP1 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/27487106 |
1.94 nM [IC50] | ||
Target ID: Q9UGN5 Gene ID: 10038.0 Gene Symbol: PARP2 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/27487106 |
|||
Target ID: Q9Y6F1 Gene ID: 10039.0 Gene Symbol: PARP3 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/27487106 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | LYNPARZA Approved UseMonotherapy in patients with deleterious or suspected deleterious germline BRCA mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Launch Date1.4189472E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.97 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30887180 |
100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
OLAPARIB blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
6.88 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30887180 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
OLAPARIB blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3.75 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30887180 |
100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
OLAPARIB blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
8.27 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30887180 |
300 mg 2 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
OLAPARIB blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
6.875 ug/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02430311 |
300 mg single, oral dose: 300 mg route of administration: oral experiment type: single co-administered: |
OLAPARIB plasma | Homo sapiens population: unhealthy age: sex: food status: |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10.9 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30887180 |
100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
OLAPARIB blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
31.7 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30887180 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
OLAPARIB blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
16.7 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30887180 |
100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
OLAPARIB blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
44 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30887180 |
300 mg 2 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
OLAPARIB blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
31.68 ug*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02430311 |
300 mg single, oral dose: 300 mg route of administration: oral experiment type: single co-administered: |
OLAPARIB plasma | Homo sapiens population: unhealthy age: sex: food status: |
|
43.91 ug*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02430311 |
300 mg 2 times / day single, oral dose: 300 mg route of administration: oral experiment type: single co-administered: |
OLAPARIB plasma | Homo sapiens population: unhealthy age: sex: food status: |
|
43.9499999999999 ug*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02430311 |
300 mg 2 times / day single, oral dose: 300 mg route of administration: oral experiment type: single co-administered: |
OLAPARIB plasma | Homo sapiens population: unhealthy age: sex: food status: |
|
36.37 ug*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02430311 |
300 mg single, oral dose: 300 mg route of administration: oral experiment type: single co-administered: |
OLAPARIB plasma | Homo sapiens population: unhealthy age: sex: food status: |
|
36.53 ug*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02430311 |
300 mg single, oral dose: 300 mg route of administration: oral experiment type: single co-administered: |
OLAPARIB plasma | Homo sapiens population: unhealthy age: sex: food status: |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.17 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30887180 |
100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
OLAPARIB blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
6.52 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30887180 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
OLAPARIB blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
18% |
OLAPARIB plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
600 mg 2 times / day steady, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: Page: p. 8 |
unhealthy n = 52 Health Status: unhealthy Condition: advanced solid tumors Population Size: 52 Sources: Page: p. 8 |
|
300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Disc. AE: Anemia, Anemia... AEs leading to discontinuation/dose reduction: Anemia (grade 1-2, 24%) Sources: Anemia (grade 3-4, 20%) Neutropenia (9%) Nausea (grade 1-2, 73%) Nausea (grade 3-4, 3%) Vomiting (grade 1-2, 34%) Vomiting (grade 3-4, 3%) |
300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Disc. AE: Fatigue, Fatigue... Other AEs: Diarrhea, Diarrhea... AEs leading to discontinuation/dose reduction: Fatigue (grade 1-2, 62%) Other AEs:Fatigue (grade 3-4, 4%) Diarrhea (grade 1-2, 31%) Sources: Diarrhea (grade 3-4, 2%) Abscess oral (grade 1-2, 19%) Aphthous ulcer (grade 1-2, 19%) Gingival abscess (grade 1-2, 19%) Gingival disorder (grade 1-2, 19%) Gingival pain (grade 1-2, 19%) Gingivitis (grade 1-2, 19%) Mouth ulceration (grade 1-2, 19%) Mucosal infection (grade 1-2, 19%) Mucosal inflammation (grade 1-2, 19%) Oral candidiasis (grade 1-2, 19%) Oral discomfort (grade 1-2, 19%) Oral herpes (grade 1-2, 19%) Oral infection (grade 1-2, 19%) Oral mucosal erythema (grade 1-2, 19%) Oral pain (grade 1-2, 19%) Oropharyngeal discomfort (grade 1-2, 19%) Oropharyngeal pain (grade 1-2, 19%) Abscess oral (grade 3-4, 1%) Aphthous ulcer (grade 3-4, 1%) Gingival abscess (grade 3-4, 1%) Gingival disorder (grade 3-4, 1%) Gingival pain (grade 3-4, 1%) Gingivitis (grade 3-4, 1%) Mouth ulceration (grade 3-4, 1%) Mucosal infection (grade 3-4, 1%) Mucosal inflammation (grade 3-4, 1%) Oral candidiasis (grade 3-4, 1%) Oral discomfort (grade 3-4, 1%) Oral herpes (grade 3-4, 1%) Oral infection (grade 3-4, 1%) Oral mucosal erythema (grade 3-4, 1%) Oral pain (grade 3-4, 1%) Oropharyngeal discomfort (grade 3-4, 1%) Oropharyngeal pain (grade 3-4, 1%) Nasopharyngitis (grade 1-4, 36%) Sinusitis (grade 1-4, 36%) Rhinitis (grade 1-4, 36%) Influenza (grade 1-4, 36%) Decreased appetite (grade 1-4, 22%) Arthralgia (grade 1-4, 30%) Myalgia (grade 1-4, 30%) Dysgeusia (grade 1-4, 27%) Headache (grade 1-2, 25%) Headache (grade 3-4, 1%) Rash (<20%) Cough (<20%) Dyspepsia (<20%) Leukopenia (<20%) Hypomagnesemia (<20%) Dizziness (<20%) Thrombocytopenia (<20%) Creatinine increased (<20%) Lymphopenia (<20%) Edema (<20%) Mean corpuscular volume increased (grade 1-4, 89%) Decreased hemoglobin (grade 1-2, 66%) Decreased hemoglobin (grade 3-4, 17%) Leukocyte count decreased (grade 1-2, 64%) Leukocyte count decreased (grade 3-4, 5%) Lymphocyte count low (grade 1-2, 56%) Lymphocyte count low (grade 3-4, 11%) Absolute neutrophil count decreased (grade 1-2, 44%) Absolute neutrophil count decreased (grade 3-4, 7%) Creatinine serum increased (grade 1-4, 44%) Platelets decreased (grade 1-2, 40%) Platelets decreased (grade 3-4, 2%) |
300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: Page: p. 99 |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: Page: p. 99 |
Disc. AE: Thrombocytopenia, Myelodysplastic syndrome... AEs leading to discontinuation/dose reduction: Thrombocytopenia (9 patients) Sources: Page: p. 99Myelodysplastic syndrome (2 patients) Acute myeloid leukemia (2 patients) |
400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Disc. AE: Nausea, Nausea... AEs leading to discontinuation/dose reduction: Nausea (grade 1-2, 61%) Sources: Nausea (grade 3-4, 3%) Vomiting (grade 1-2, 39%) Vomiting (grade 3-4, 4%) Fatigue (grade 1-2, 58%) Fatigue (grade 3-4, 8%) Anemia (grade 1-2, 75%) Anemia (grade 3-4, 15%) Thrombocytopenia (grade 1-2, 27%) Thrombocytopenia (grade 3-4, 3%) |
400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Sources: |
Disc. AE: Pneumonitis... AEs leading to discontinuation/dose reduction: Pneumonitis (grade 5, <1%) Sources: |
400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Other AEs: Anemia, Anemia... Other AEs: Anemia (grade 1-2, 16%) Sources: Anemia (grade 3-4, 18%) Abdominal discomfort (grade 1-2, 35%) Abdominal discomfort (grade 3-4, 8%) Decreased appetite (grade 1-2, 21%) Decreased appetite (grade 3-4, 1%) Diarrhea (grade 1-2, 30%) Diarrhea (grade 3-4, 1%) Dyspepsia (grade 1-4, 25%) Asthenia (grade 1-2, 58%) Asthenia (grade 3-4, 8%) Nasopharyngitis (grade 1-4, 26%) Arthralgia (grade 1-4, 21%) Musculoskeletal pain (grade 1-4, 21%) Myalgia (grade 1-4, 22%) Neutropenia (grade 1-2, 18%) Neutropenia (grade 3-4, 7%) Lymphopenia (grade 1-2, 39%) Lymphopenia (grade 3-4, 17%) Mean corpuscular volume increased (grade 1-4, 57%) Creatinine increased (grade 1-2, 28%) Creatinine increased (grade 3-4, 2%) Cough (10-20) Constipation (10-20) Dysgeusia (10-20) Peripheral edema (10-20) Back pain (10-20) Dizziness (10-20) Headache (10-20) Urinary tract infection (10-20) Dyspnea (10-20) Rash (10-20) Leukopenia (1-10) Stomatitis (1-10) Peripheral neuropathy (1-10) Pyrexia (1-10) Hypomagnesemia (1-10) Hyperglycemia (1-10) Anxiety (1-10) Depression (1-10) Insomnia (1-10) Dysuria (1-10) Urinary incontinence (1-10) Vulvovaginal disorder (1-10) Dry skin (1-10) Eczema (1-10) Pruritis (1-10) Hypertension (1-10) Venous thrombosis (1-10) Hot flush (1-10) |
400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 2618 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 2618 Sources: |
Disc. AE: Myelodysplastic syndrome, Acute myeloid leukemia... AEs leading to discontinuation/dose reduction: Myelodysplastic syndrome (grade 5, <1%) Sources: Acute myeloid leukemia (grade 5, <1%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Neutropenia | 9% Disc. AE |
300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Anemia | grade 1-2, 24% Disc. AE |
300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Vomiting | grade 1-2, 34% Disc. AE |
300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Nausea | grade 1-2, 73% Disc. AE |
300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Anemia | grade 3-4, 20% Disc. AE |
300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Nausea | grade 3-4, 3% Disc. AE |
300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Vomiting | grade 3-4, 3% Disc. AE |
300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Cough | <20% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Creatinine increased | <20% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Dizziness | <20% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Dyspepsia | <20% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Edema | <20% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Hypomagnesemia | <20% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Leukopenia | <20% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Lymphopenia | <20% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Rash | <20% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Thrombocytopenia | <20% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Abscess oral | grade 1-2, 19% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Aphthous ulcer | grade 1-2, 19% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Gingival abscess | grade 1-2, 19% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Gingival disorder | grade 1-2, 19% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Gingival pain | grade 1-2, 19% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Gingivitis | grade 1-2, 19% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Mouth ulceration | grade 1-2, 19% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Mucosal infection | grade 1-2, 19% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Mucosal inflammation | grade 1-2, 19% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Oral candidiasis | grade 1-2, 19% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Oral discomfort | grade 1-2, 19% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Oral herpes | grade 1-2, 19% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Oral infection | grade 1-2, 19% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Oral mucosal erythema | grade 1-2, 19% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Oral pain | grade 1-2, 19% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Oropharyngeal discomfort | grade 1-2, 19% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Oropharyngeal pain | grade 1-2, 19% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Headache | grade 1-2, 25% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Diarrhea | grade 1-2, 31% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Platelets decreased | grade 1-2, 40% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Absolute neutrophil count decreased | grade 1-2, 44% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Lymphocyte count low | grade 1-2, 56% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Fatigue | grade 1-2, 62% Disc. AE |
300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Leukocyte count decreased | grade 1-2, 64% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Decreased hemoglobin | grade 1-2, 66% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Decreased appetite | grade 1-4, 22% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Dysgeusia | grade 1-4, 27% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Arthralgia | grade 1-4, 30% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Myalgia | grade 1-4, 30% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Influenza | grade 1-4, 36% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Nasopharyngitis | grade 1-4, 36% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Rhinitis | grade 1-4, 36% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Sinusitis | grade 1-4, 36% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Creatinine serum increased | grade 1-4, 44% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Mean corpuscular volume increased | grade 1-4, 89% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Abscess oral | grade 3-4, 1% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Aphthous ulcer | grade 3-4, 1% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Gingival abscess | grade 3-4, 1% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Gingival disorder | grade 3-4, 1% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Gingival pain | grade 3-4, 1% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Gingivitis | grade 3-4, 1% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Headache | grade 3-4, 1% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Mouth ulceration | grade 3-4, 1% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Mucosal infection | grade 3-4, 1% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Mucosal inflammation | grade 3-4, 1% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Oral candidiasis | grade 3-4, 1% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Oral discomfort | grade 3-4, 1% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Oral herpes | grade 3-4, 1% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Oral infection | grade 3-4, 1% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Oral mucosal erythema | grade 3-4, 1% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Oral pain | grade 3-4, 1% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Oropharyngeal discomfort | grade 3-4, 1% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Oropharyngeal pain | grade 3-4, 1% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Lymphocyte count low | grade 3-4, 11% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Decreased hemoglobin | grade 3-4, 17% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Diarrhea | grade 3-4, 2% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Platelets decreased | grade 3-4, 2% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Fatigue | grade 3-4, 4% Disc. AE |
300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Leukocyte count decreased | grade 3-4, 5% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Absolute neutrophil count decreased | grade 3-4, 7% | 300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: |
Acute myeloid leukemia | 2 patients Disc. AE |
300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: Page: p. 99 |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: Page: p. 99 |
Myelodysplastic syndrome | 2 patients Disc. AE |
300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: Page: p. 99 |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: Page: p. 99 |
Thrombocytopenia | 9 patients Disc. AE |
300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: Page: p. 99 |
unhealthy n = 195 Health Status: unhealthy Condition: gBRCAm ovarian cancer Population Size: 195 Sources: Page: p. 99 |
Thrombocytopenia | grade 1-2, 27% Disc. AE |
400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Vomiting | grade 1-2, 39% Disc. AE |
400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Fatigue | grade 1-2, 58% Disc. AE |
400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Nausea | grade 1-2, 61% Disc. AE |
400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Anemia | grade 1-2, 75% Disc. AE |
400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Anemia | grade 3-4, 15% Disc. AE |
400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Nausea | grade 3-4, 3% Disc. AE |
400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Thrombocytopenia | grade 3-4, 3% Disc. AE |
400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Vomiting | grade 3-4, 4% Disc. AE |
400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Fatigue | grade 3-4, 8% Disc. AE |
400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Pneumonitis | grade 5, <1% Disc. AE |
400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Sources: |
Anxiety | 1-10 | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Depression | 1-10 | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Dry skin | 1-10 | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Dysuria | 1-10 | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Eczema | 1-10 | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Hot flush | 1-10 | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Hyperglycemia | 1-10 | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Hypertension | 1-10 | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Hypomagnesemia | 1-10 | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Insomnia | 1-10 | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Leukopenia | 1-10 | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Peripheral neuropathy | 1-10 | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Pruritis | 1-10 | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Pyrexia | 1-10 | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Stomatitis | 1-10 | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Urinary incontinence | 1-10 | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Venous thrombosis | 1-10 | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Vulvovaginal disorder | 1-10 | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Back pain | 10-20 | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Constipation | 10-20 | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Cough | 10-20 | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Dizziness | 10-20 | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Dysgeusia | 10-20 | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Dyspnea | 10-20 | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Headache | 10-20 | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Peripheral edema | 10-20 | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Rash | 10-20 | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Urinary tract infection | 10-20 | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Anemia | grade 1-2, 16% | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Neutropenia | grade 1-2, 18% | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Decreased appetite | grade 1-2, 21% | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Creatinine increased | grade 1-2, 28% | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Diarrhea | grade 1-2, 30% | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Abdominal discomfort | grade 1-2, 35% | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Lymphopenia | grade 1-2, 39% | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Asthenia | grade 1-2, 58% | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Arthralgia | grade 1-4, 21% | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Musculoskeletal pain | grade 1-4, 21% | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Myalgia | grade 1-4, 22% | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Dyspepsia | grade 1-4, 25% | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Nasopharyngitis | grade 1-4, 26% | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Mean corpuscular volume increased | grade 1-4, 57% | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Decreased appetite | grade 3-4, 1% | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Diarrhea | grade 3-4, 1% | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Lymphopenia | grade 3-4, 17% | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Anemia | grade 3-4, 18% | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Creatinine increased | grade 3-4, 2% | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Neutropenia | grade 3-4, 7% | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Abdominal discomfort | grade 3-4, 8% | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Asthenia | grade 3-4, 8% | 400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 223 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 223 Sources: |
Acute myeloid leukemia | grade 5, <1% Disc. AE |
400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 2618 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 2618 Sources: |
Myelodysplastic syndrome | grade 5, <1% Disc. AE |
400 mg 2 times / day steady, oral Recommended|MTD Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy n = 2618 Health Status: unhealthy Condition: gBRCA-mutated advanced ovarian cancer Population Size: 2618 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no [Inhibition >100 uM] | ||||
no [Inhibition >100 uM] | ||||
no [Inhibition >100 uM] | ||||
no [Inhibition >100 uM] | ||||
no [Inhibition >100 uM] | ||||
no [Inhibition >100 uM] | ||||
no [Inhibition >100 uM] | ||||
no [Inhibition >100 uM] | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
yes [IC50 18.4 uM] | ||||
yes [IC50 19.9 uM] | ||||
yes [IC50 20.3 uM] | ||||
yes [IC50 37.9 uM] | ||||
yes [IC50 47.1 uM] | ||||
yes [IC50 5.5 uM] | ||||
yes [Inhibition 100 uM] | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
yes | ||||
yes | ||||
yes | ||||
yes | yes (co-administration study) Comment: Itraconazole (strong CYP3A inhibitor) increased the AUC of olaparib by 2.7-fold and PBPK modeling predicted that fluconazole (moderate CYP3A inhibitor) would likely increase olaparib AUC by 2-fold. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206162Orig1s000ClinPharmR.pdf#page=4 Page: - |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
A FlashPlate assay for the identification of PARP-1 inhibitors. | 2003 Jun |
|
4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. | 2008 Oct 23 |
|
Are current drug development programmes realising the full potential of new agents? The scenario. | 2009 |
|
Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. | 2009 Aug |
|
Triple-negative breast cancer: novel therapies and new directions. | 2009 Aug 20 |
|
Synthetic lethality: a framework for the development of wiser cancer therapeutics. | 2009 Oct 27 |
|
Recent advances in managing triple-negative breast cancers. | 2009 Sep 28 |
|
Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers. | 2010 |
|
Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms. | 2010 |
|
Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. | 2010 |
|
Targeted therapy in ovarian cancer. | 2010 |
|
A current review of targeted therapeutics for ovarian cancer. | 2010 |
|
The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer. | 2010 |
|
Biology-driven cancer drug development: back to the future. | 2010 Apr 12 |
|
Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. | 2010 Feb 15 |
|
Gateways to clinical trials. | 2010 Jan-Feb |
|
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. | 2010 Jul 24 |
|
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. | 2010 Jul 24 |
|
Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. | 2010 Jun |
|
Society for biomolecular sciences - 16th annual conference & exhibition - advancing the science of drug discovery. | 2010 Jun |
|
Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future. | 2010 Mar-Apr |
|
Multiple roles of BRIT1/MCPH1 in DNA damage response, DNA repair, and cancer suppression. | 2010 May |
|
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. | 2010 May 20 |
|
Does race affect outcomes in triple negative breast cancer? | 2010 May 7 |
|
Molecule of the month. Olaparib. | 2010 Nov |
|
Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. | 2010 Nov 9 |
|
Role for the mammalian Swi5-Sfr1 complex in DNA strand break repair through homologous recombination. | 2010 Oct 14 |
|
Gateways to clinical trials. | 2010 Sep |
|
PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers. | 2010 Sep |
|
Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil. | 2011 |
|
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. | 2011 Jul |
|
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. | 2012 Nov 1 |
Sample Use Guides
400 mg (eight 50 mg capsules) taken twice daily, for a total daily dose of 800 mg. Continue treatment until disease progression or unacceptable toxicity.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=18800822
30-100 nM in SW620 cells
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 23:07:12 UTC 2023
by
admin
on
Wed Jul 05 23:07:12 UTC 2023
|
Record UNII |
WOH1JD9AR8
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000191623
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
LYNPARZA (AUTHORIZED: OVARIAN NEOPLASMS)
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
||
|
FDA ORPHAN DRUG |
419013
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
||
|
FDA ORPHAN DRUG |
417613
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/07/501
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
||
|
FDA ORPHAN DRUG |
409213
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
||
|
WHO-ATC |
L01XX46
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
||
|
FDA ORPHAN DRUG |
655318
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
||
|
NCI_THESAURUS |
C62554
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
WOH1JD9AR8
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
PRIMARY | |||
|
SUB32234
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
PRIMARY | |||
|
100000124466
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
PRIMARY | |||
|
M8185
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL521686
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
PRIMARY | |||
|
4907
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
PRIMARY | |||
|
C71721
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
PRIMARY | |||
|
747856
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
PRIMARY | |||
|
8685
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
PRIMARY | |||
|
1597582
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
PRIMARY | RxNorm | ||
|
7519
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
PRIMARY | |||
|
WOH1JD9AR8
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
PRIMARY | |||
|
763113-22-0
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
PRIMARY | |||
|
23725625
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
PRIMARY | |||
|
DB09074
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
PRIMARY | |||
|
C531550
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
PRIMARY | |||
|
83766
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
PRIMARY | |||
|
Olaparib
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
PRIMARY | |||
|
OLAPARIB
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
PRIMARY | |||
|
DTXSID60917988
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
PRIMARY | |||
|
N0000191622
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
PRIMARY | Poly(ADP-Ribose) Polymerase Inhibitors [MoA] | ||
|
BC-28
Created by
admin on Wed Jul 05 23:07:13 UTC 2023 , Edited by admin on Wed Jul 05 23:07:13 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
DT40 cells cytotoxicity
BINDING
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
TRANSPORTER -> SUBSTRATE |
|
||
|
EXCRETED UNCHANGED |
FECAL
|
||
|
TRANSPORTER -> INHIBITOR |
INHIBITOR
IC50
|
||
|
TRANSPORTER -> INHIBITOR |
The clinical relevance of these findings is unknown.
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
TRANSPORTER -> INHIBITOR |
INHIBITOR
IC50
|
||
|
TRANSPORTER -> INHIBITOR |
INHIBITOR
IC50
|
||
|
TRANSPORTER -> INHIBITOR |
INHIBITOR
IC50
|
||
|
EXCRETED UNCHANGED |
URINE
|
||
|
TRANSPORTER -> INHIBITOR |
INHIBITOR
IC50
|
||
|
METABOLIC ENZYME -> INHIBITOR |
Inhibitor at higher concentrations than are clinically achieved.
MINOR
|
||
|
TRANSPORTER -> INHIBITOR |
INHIBITOR
IC50
|
||
|
SOLVATE->ANHYDROUS | |||
|
TRANSPORTER -> INHIBITOR |
INHIBITOR
IC50
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||